BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Kobierski Jan (Jagiellonian University, Medical College, Krakow, Poland), Hałdaś Matuesz (HTA Consulting, Kraków, Poland), Władysiuk Magdalena (HTA Consulting, Kraków, Poland)
Hepatitis C - The Implications and The Need for Change in The Health Care System in Poland
Journal of Health Policy and Outcomes Research, 2014, nr 2, s. 26-34, rys., bibliogr. 68 poz.
Słowa kluczowe
Opieka zdrowotna, Choroby
Health care, Illness
Hepatitis C is a disease spreading across the world. It is estimated that more than 185 million people are potentially infected with HCV. Each year approximately 350 thousand people die of diseases resulting from HCV. In Poland about 231 thousand people are believed to be infected, with up to 85% of them unaware of their progressive illness. Hepatitis C leads to serious complications in the liver and, consequently, can lead to death. The disease generates appreciable costs associated with the treatment of the complications of HCV in the advanced stages of the disease as well as lost productivity. As there is no vaccine against HCV, hepatitis C treatment is the only way to eradicate the virus. This is now possible with new therapies. This article presents the burden of hepatitis C and its changing dynamics in the context of hepatitis B and HIV in Poland. The natural history, the costs generated by the disease, available current therapies and suggested ways forward are also discussed in the article(original abstract)
Pełny tekst
  1. Maasoumy B., Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012; 26: 401-412
  2. Madaliński K., Flisiak R., Halota W. et al. Report prepared for The World Hepatitis Day - 28th July 2013; Available from: for Hepatitis Day WHO.pdf
  3. Madaliński K., Aktualny algorytm diagnostyki HCV; Available from: ca_11.10.2012/Prezentacje/P2.ppt
  4. Gajewski P. Interna Szczeklika - mały podręcznik 2014/2015; Available from:
  5. WHO. The 63rd World Health Assemby. Resolutions and Decisions Annexes; Available from:
  6. European Parliament. Written Declaration submitted under Rule 123 of the Rules of Procedure on Hepatitis B and C; Available from:
  7. WHO. Viral hepatitis. Report by the Secretariat. A63/15; Available from:
  8. Ly KN., Xing J., Klevens RM. et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156: 271-278
  9. Mühlberger N., Schwarzer R., Lettmeier B. et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health, 2009; 9: 34
  10. ECDC. Annual Epidemiological Report: Reporting on 2011 surveillance data and 2012 epidemic intelligence data; Available from:
  11. Bogucki M. Diagnostyka i terapia przewlekłego wirusowego zapalenia wątroby typu C (wirusem HCV) w Polsce: raport - rekomendacje 2013-2014; Instytut Ochrony Zdrowia; Available from:
  12. Zieliński A. Wirusowe zapalenie wątroby typu B i C w Polsce w latach 1993-2011; Available from: - HCV - projekty.pptx;
  13. TNS OBOP. Wiedza na temat wirusowego zapalenia wątroby. Raport z badania. Available from:
  14. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection; Available from:
  15. Esteban JI., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008; 48:148-162
  16. Godzik P., Kołakowska A., Madaliński K. et al. Prevalence of anti-HCV antibodies among adults in Poland-results of cross-sectional study in general population. Przegla̧d Epidemiol. 2012; 66: 575-580
  17. Flisiak R., Halota W., Horban A. et al. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011; 23: 1213-1217
  18. Prometeusze. Information about hepatitis B and hepatitis C; Available from:
  19. Statement of the President of the National Health Fund.; Available from: 21.2.2013 ; [Accessed:17.10.2007]
  20. Godala M., Szatko F. Zgłaszalność chorób zakaźnych. Cz. I. Ocena świadomości lekarzy dotycząca zgłaszania chorób zakaźnych do inspekcji sanitarnej. Probl Hig Epidemiol. 2010; 91: 198-205
  21. NIPH - NIH. Infectious diseases and poisonings in Poland (annual reports); Available from:
  22. ECDC. Surveillance and prevention of hepatitis B and C in Europe. European Centre for Disease Prevention and Control; 2010. Available from:
  23. Smith DB., Bukh J., Kuiken C. et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatol Baltim Md. 2014; 59: 318-327
  24. WHO. Hepatitis C. Global Alert and Responsis; Available from:
  25. Panasiuk A., Flisiak R., Mozer-Lisewska I. et al. Distribution of HCV genotypes in Poland. Przegla̧d Epidemiol. 2013; 67:11-16, 99-103
  26. Cieśla A., Mach T. Chronic viral hepatitis - current epidemiological, clinical and therapeutic challenge. Przegląd Gastroenterol. 2007; 2: 69-73
  27. CDC. Hepatitis C Information For the Health Professional; Available from:
  28. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2014; 60: 392-420
  29. Chen SL., Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci. 2006; 3: 47-52
  30. Thein H-H., Yi Q., Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatol Baltim Md. 2008; 48: 418-431
  31. Juszczyk J., Baka-Cwierz B., Beniowski M. et al. Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report). Przegla̧d Epidemiol. 2005; 59: 651-660
  32. Juszczyk J., Białkowska J., Bolewska B. Pegylowany interferon alfa-2b i rybawiryna w leczeniu przewlekłego wirusowego zapalenia wątroby typu C. Pol Merkuriusz Lek. 2004; XVI: 353
  33. Kołakowska-Rządzka A., Berak H., Wasilewski M. Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavarin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatol Baltim Md. 2008; 48: 878A
  34. Guido M., Mangia A., Faa G., et al. Chronic viral hepatitis: the histology report. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2011; 43 Suppl 4: S331-S343
  35. Hatzakis A., Van Damme P., Alcorn K, et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat. 2013; 20 Suppl 2:1-20
  36. El-Serag HB., Kramer JR., Chen GJ. et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011; 60: 992-997
  37. Ollivier I., Dauvois B., Guittet L. et al. Survival improvement in Child-Pugh C cirrhotic patients with hepatocellular carcinoma diagnosed during 1990-2002. Gastroentérologie Clin Biol. 2010; 34: 288-296
  38. Borie F., Bouvier A-M., Herrero A. et al. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol. 2008; 98: 505-509
  39. Małkowski P., Czerwiński J., Pacholczyk M. et al. Current status of liver transplantation. Przegla̧d Epidemiol. 2005; 59: 559-566
  40. Małkowski P., Czerwiński J., Wasiak D. et al. Liver transplantation in Poland in comparison to European results. Med Sci Rev - Hepatol. 2007; 7: 3-8
  41. Mukherjee S., Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology. 2008; 134: 1777-1788
  42. Poltransplant; Available from:
  43. Wawrzynowicz-Syczewska M. Przewlekłe wirusowe zapalenie wątroby typu C jako wskazanie do retransplantacji wątroby. Med Sci Rev - Hepatol. 2011; 11: 57-59
  44. Pawłowska J., Teisseyre M., Jankowska I. et al. Preliminary results and complications of HCV treatment after liver transplantation. Przegla̧d Epidemiol. 2006; 60: 677-683
  45. Liang TJ., Ghany MG. Current and Future Therapies for Hepatitis C Virus Infection. N Engl J Med. 2013; 368: 1907-1917
  46. Brennan T., Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014; 312: 593-594
  47. Halota W., Flisiak R., Boroń-Kaczmarska A. et al. Standardy leczenia wirusowych zapaleń wątroby typu C. Rekomendacje Polskiej Grupy Ekspertów HCV. Przegląd Epidemiol. 2012; 66: 83-88
  48. EMA. Product Characteristics - Rebetol (ribavirin); Available from:
  49. EMA. Product Characteristics - PegIntron (peginterferon alfa-2b); Available from:
  50. Jiménez-Sousa MA., Fernández-Rodríguez A., Guzmán-Fulgencio M. et al. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013; 11: 6
  51. Khuroo MS., Khuroo MS., Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2004; 20: 931-938
  52. Aljumah AA., Murad MH. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis. Hepatol Res Off J Jpn Soc Hepatol. 2013; 43: 1255-1263
  53. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55: 1350-1359
  54. EMA. Product Characteristics - Victrelis (boceprevir); Available from:
  55. EMA. Product Characteristics - Incivo (telaprevir); Available from:
  56. EMA. Product Characteristics - Sovaldi (sofosbuvir); Available from:
  57. EMA. Product Characteristics - Olysio (simeprevir); Available from: _Product_Information/hu [Internet]. man/002777/WC500167867.pdf
  58. EMA. Product Characteristics - Daklinza (daclatasvir); Available from:
  59. EMA. Product Characteristics - Harvoni (sofosbuvir/ledipasvir); Available from:
  60. European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C. Available from:; [Accessed: 2015]
  61. Park C., Jiang S., Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014;.39:.14-24
  62. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. Available from:
  63. EASL Recommendations on Treatment of Hepatitis C 2014. Available from:
  64. Jaroszewicz J., Flisiak R., Dusheiko G. A pill for HCV - myth or foreseeable future? Liver Int. 2014; 34: 6-11
  65. Flisiak R., Jaroszewicz J., Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013; 18: 461-475
  66. Kowdley KV., Gordon SC., Reddy KR. et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. N Engl J Med. 2014;.370:.1879-1888
  67. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2011; 17: 107-115
  68. Rosińska M., Parda N., Stepień M. Hepatitis C in Poland in 2011. Przegla̧d Epidemiol. 2013;.67:.247-251, 353-356
Cytowane przez
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu